Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Cardlytics Inc’s stock clocked out at $0.92, up 3.44% from its previous closing price of $0.89. In other words, the price has increased by $3.44 from its previous closing price. On the day, 0.66 million shares were traded. CDLX stock price reached its highest trading level at $0.9299 during the session, while it also had its lowest trading level at $0.8669.
Ratios:
To gain a deeper understanding of CDLX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.16. In the meantime, Its Debt-to-Equity ratio is 3.75 whereas as Long-Term Debt/Eq ratio is at 2.95.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Evercore ISI on October 11, 2024, initiated with a In-line rating and assigned the stock a target price of $4.
BofA Securities Downgraded its Neutral to Underperform on August 15, 2024, whereas the target price for the stock was revised from $4 to $3.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 18 ’25 when SOSIN CLIFFORD sold 200,000 shares for $1.14 per share. The transaction valued at 228,220 led to the insider holds 5,399,023 shares of the business.
SOSIN CLIFFORD sold 200,000 shares of CDLX for $224,540 on Aug 19 ’25. The 10% Owner now owns 5,199,023 shares after completing the transaction at $1.12 per share. On Aug 18 ’25, another insider, Gupta Amit, who serves as the Chief Executive Officer of the company, sold 68,260 shares for $1.12 each. As a result, the insider received 76,792 and left with 560,444 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDLX now has a Market Capitalization of 49004564 and an Enterprise Value of 222671568. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.18 while its Price-to-Book (P/B) ratio in mrq is 0.83. Its current Enterprise Value per Revenue stands at 0.836 whereas that against EBITDA is -7.068.
Stock Price History:
The Beta on a monthly basis for CDLX is 1.22, which has changed by -0.7314869 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, CDLX has reached a high of $5.24, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is -42.94%, while the 200-Day Moving Average is calculated to be -61.14%.
Shares Statistics:
It appears that CDLX traded 1.52M shares on average per day over the past three months and 1283370 shares per day over the past ten days. A total of 52.99M shares are outstanding, with a floating share count of 50.33M. Insiders hold about 5.46% of the company’s shares, while institutions hold 45.44% stake in the company. Shares short for CDLX as of 1755216000 were 7052621 with a Short Ratio of 4.65, compared to 1752537600 on 6416322. Therefore, it implies a Short% of Shares Outstanding of 7052621 and a Short% of Float of 15.439998999999998.
Earnings Estimates
The dynamic stock of Cardlytics Inc (CDLX) is currently being evaluated by a team of 3.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.04 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.46 and -$0.8 for the fiscal current year, implying an average EPS of -$0.62. EPS for the following year is -$0.45, with 3.0 analysts recommending between -$0.3 and -$0.61.
Revenue Estimates
In the current quarter, 4 analysts expect revenue to total $56.64M. It ranges from a high estimate of $63.8M to a low estimate of $53.07M. As of the current estimate, Cardlytics Inc’s year-ago sales were $67.06MFor the next quarter, 4 analysts are estimating revenue of $58.85M. There is a high estimate of $62.8M for the next quarter, whereas the lowest estimate is $55.81M.
A total of 4 analysts have provided revenue estimates for CDLX’s current fiscal year. The highest revenue estimate was $243.4M, while the lowest revenue estimate was $234.03M, resulting in an average revenue estimate of $238.54M. In the same quarter a year ago, actual revenue was $278.3MBased on 5 analysts’ estimates, the company’s revenue will be $228.85M in the next fiscal year. The high estimate is $250.1M and the low estimate is $202.24M.
